amikacin has been researched along with Pseudomonas Infections in 308 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 107 (34.74) | 18.7374 |
| 1990's | 44 (14.29) | 18.2507 |
| 2000's | 65 (21.10) | 29.6817 |
| 2010's | 71 (23.05) | 24.3611 |
| 2020's | 21 (6.82) | 2.80 |
| Authors | Studies |
|---|---|
| Furuno, JP; Graffunder, E; Graves, J; Lodise, TP; Lomaestro, B; McGregor, JC; McNutt, LA; Miller, CD | 1 |
| Adams, J; de Oliveira Garcia, D; Doi, Y; Paterson, DL | 1 |
| Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
| Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
| Bajolet, O; Berthelot, P; Bingen, E; Couetdic, G; Favre, R; Grattard, F; Hocquet, D; Husson, MO; Jeannot, K; Mariani-Kurkdjian, P; Marty, N; Plésiat, P; Roussel-Delvallez, M | 1 |
| Bertrand, X; Blanc, K; Hocquet, D; Monnet, DL; Muller, A; Plésiat, P; Talon, D | 1 |
| Attree, I; Elsen, S; Jeannot, K; Köhler, T; Plésiat, P; van Delden, C | 1 |
| Carrillo, B; Esparza-Ahumada, S; Garza-Ramos, U; Hernández, E; Jones, RN; Morfin-Otero, R; Rodriguez-Noriega, E; Sader, HS; Sanchez, A; Silva-Sanchez, J | 1 |
| Albertí, S; Beceiro, A; Bou, G; Garau, M; Gutiérrez, O; Juan, C; Oliver, A; Pérez, JL | 1 |
| Duljasz, W; Gniadkowski, M; Jebelean, C; Sitter, S; Wojna, A | 1 |
| Gales, AC; Nordmann, P; Picão, RC; Poirel, L | 2 |
| Attrée, I; Ducruix, A; El Garch, F; Llanes, C; Muller, C; Phan, G; Plésiat, P; Vettoretti, L | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Giske, CG; Hermansen, NO; Leegaard, TM; Lia, A; Rajendra, Y; Ranheim, TE; Rydberg, J; Samuelsen, O; Sundsfjord, A; Toleman, MA; Walder, M; Walsh, TR | 1 |
| Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Beceiro, A; Bou, G; Doumith, M; Livermore, DM; Tomás, M; Turton, JF; Warner, M; Woodford, N | 1 |
| Abele-Horn, M; Claus, H; Elias, J; Engelhardt, K; Frosch, M; Joseph, B; Oesterlein, A; Schoen, C; Turnwald, D; Valenza, G | 1 |
| Bertrand, X; Dehecq, B; Hocquet, D; Mariotte, P; Plésiat, P; Talon, D | 1 |
| Abramite, JA; Arcari, JT; Barham, RA; Brown, MF; Che, Y; Chen, JM; Chung, SW; Collantes, EM; Desbonnet, C; Doroski, M; Doty, J; Engtrakul, JJ; Harris, TM; Huband, M; Knafels, JD; Leach, KL; Liu, S; Marfat, A; Marra, A; McElroy, E; Melnick, M; Menard, CA; Montgomery, JI; Mullins, L; Noe, MC; O'Donnell, J; Oliver, R; Penzien, J; Plummer, MS; Price, LM; Reilly, U; Shanmugasundaram, V; Thoma, C; Uccello, DP; Warmus, JS; Wishka, DG | 1 |
| Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hunt, DK; Sun, C; Sutcliffe, JA; Xiao, XY | 1 |
| Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
| Chen, CL; Deng, Y; Fyfe, C; Grossman, TH; Hunt, DK; Sun, C; Sutcliffe, JA; Xiao, XY | 1 |
| Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
| Honda, A; Ikeda, M; Kurokawa, M; Maki, H; Moriya, K; Sato, M; Toyama, K; Yamaguchi, R | 1 |
| Haider Naqvi, SZ; Malik, A; Muddassir, M; Mumtaz, K; Munir, S; Raza, A; Shoaib Ahmed, S; Waqas, K | 1 |
| Gebrecherkos, T; Mekonnen, H; Molla Fenta, G; Seid, A | 1 |
| Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
| Chen, SM; Chen, TT; Liu, HY | 1 |
| Ai, MY; Chen, BL; Chuang, HC; Lee, WY; Lee, YJ; Liu, HY; Lu, HE; Tsao, LH; Wang, EY | 1 |
| Coria-Jiménez, VR; Cuevas-Schacht, F; Gerónimo-Gallegos, A; Gutiérrez-Santana, JC; López-López, M; Martínez-Corona, MB; Toscano-Garibay, JD | 1 |
| Choi, YJ; Jeong, SH; Junglim, K; Kim, HS; Kim, YA; Kim, YR; Ryoo, NH; Shin, JH; Shin, KS; Uh, Y | 1 |
| Barzegar, KEF; Barzegar, PEF; Farjanikish, G; Hayati, FZ; Ranjbar, R; Tahmasebi, E; Tebyaniyan, H; Yazdanian, M | 1 |
| Jia, P; Xu, Y; Yang, Q; Yu, W; Zhang, H; Zhu, Y | 1 |
| Artigas, A; Battaglini, D; Bobi, J; Cabrera, R; Camprubí-Rimblas, M; Fernández-Barat, L; Ferrer-Segarra, A; Frigola, G; Kiarostami, K; Li Bassi, G; Martinez, D; Meli, A; Motos, A; Nicolau, DP; Pagliara, F; Pelosi, P; Rigol, M; Torres, A; Vila, J; Yang, H; Yang, M | 1 |
| Baniasadi, S; Hassanzad, M; Kouhestani, F | 1 |
| Huang, Y; Liu, H; Lu, W; Peng, J; Qin, G; Wu, D; Xiao, J | 1 |
| Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Siroosi, M | 1 |
| Bilton, D; Cipolli, M; Clancy, JP; Eagle, G; Fajac, I; Galeva, I; Gupta, R; Konstan, MW; Liu, K; McGinnis, JP; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A | 1 |
| Pliska, NN | 1 |
| Cabot, G; Fernández-Cuenca, F; López-Cerero, L; López-Méndez, J; Oliver, A; Pascual, Á; Portillo, I; Recacha, E; Rodríguez-Baño, J | 1 |
| Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E | 1 |
| Aprile, A; Bongiorno, D; Cervo, A; Grossi, P; Luca, A; Medaglia, AA; Mezzatesta, ML; Mularoni, A; Pilato, M; Stefani, S | 1 |
| Bilton, D; Ciesielska, M; Cipolli, M; Clancy, JP; Fajac, I; Galeva, I; Jumadilova, Z; Konstan, MW; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A | 1 |
| Deng, XY; Huang, SH; Li, YH; Liu, CF; Peng, L; Xiao, Y; Yang, SJ; Zeng, LT; Zhang, TS | 1 |
| Borgatta, B; Gattarello, S; Imbiscuso, AT; Larrosa, MN; Lujàn, M; Mazo, CA; Rello, J | 1 |
| Akhi, MT; Ghotaslou, R; Kafil, HS; Khalili, Y; Naghili, B; Sheikhalizadeh, V; Yousefi, S | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Cai, Y; Wang, J; Wang, R; Yang, D | 1 |
| Da Dalt, L; Guarnieri, M; Lucca, F; Muffato, G; Rigoli, R; Ros, M | 1 |
| Arnaout, HH; Elshimy, AAA; Mostafa, MS; Nasr, AM | 1 |
| Barth, AL; Martins, AF; Nunes, LS; Wilhelm, CM | 1 |
| Garcia-Morales, E; Gofman, N; To, K; Whitman, M | 1 |
| Charbek, E; Rowbotham, NJ; Smith, S | 1 |
| Fernández Esgueva, M; Ferrer Cerón, I; García-Lechuz Moya, JM; López-Calleja, AI; Morilla Morales, E; Nuñez Medina, R; Rezusta López, A; Sahagún Pareja, J; Viñuelas Bayon, J | 1 |
| Aguilera Xiol, E; Amaro, R; Antonelli, M; Artigas, A; Blasi, F; Bobi, J; Bringué, J; Carbonara, M; Chiurazzi, C; Comaru, T; Comino Trinidad, O; De Rosa, F; Fernandez-Barat, L; Fuster, C; Li Bassi, G; Marti, JD; Montgomery, AB; Motos, A; Nicolau, DP; Pelosi, P; Ramirez, J; Ranzani, OT; Rigol, M; Rinaudo, M; Saco, MA; Senussi, T; Torres, A; Yang, H | 1 |
| Bošković, L; Božić, DD; Ivković, B; Milenković, M; Ušjak, D | 1 |
| Gilbert, DN | 1 |
| Akamatsu, T; Ikeue, H; Kitahara, T; Kitamura, M; Maeda, Y; Mori, T; Muraki, Y; Okuda, M; Shiraishi, T; Tadano, K; Takada, K; Tsugita, M; Yamada, T | 1 |
| Billings, J; Burns, JL; Clancy, JP; Dupont, L; Fustik, S; Goss, CH; Govan, JR; Gupta, R; Konstan, MW; Lymp, J; Minic, P; Quittner, AL; Ramsey, B; Rubenstein, RC; Saiman, L; Young, KR | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Fukushima, S; Matsumoto, T; Mizuno, Y; Nakamura, I; Sato, A; Tsukimori, A; Yamaguchi, T | 1 |
| Clancy, JP; Ehsan, Z; Wetzel, JD | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Gupta, R; Hammel, JP; Okusanya, OO | 1 |
| Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M | 1 |
| Alba, L; Behta, M; Clock, SA; Della-Latta, P; Furuya, EY; Jenkins, SG; Jia, H; Kubin, CJ; Oliveira, AP; Patel, SJ; Rhee, K; Saiman, L; Schuetz, AN; Weisenberg, SA; Whittier, S; Zhou, JJ | 1 |
| Fiel, SB | 1 |
| Ratjen, F; Waters, V | 1 |
| Cooke, K; Torres, AR | 1 |
| Fukui, E; Hasegawa, A; Okada, Y; Usui, R | 1 |
| Alm, RA; Corbeil, J; Déraspe, M; Gardner, H; Kos, VN; McLaughlin, RE; Roy, PH; Whiteaker, JD | 1 |
| Birkun, AA; Fedosov, MI; Krivorutchenko, YL; Kubyshkin, AV; Novikov, NY; Postnikova, ON; Snitser, AA | 1 |
| Eksi, F; Nazli, E; Zer, Y | 1 |
| Bursle, E; Cotta, MO; Gowen, B; Lipman, J; McWhinney, B; Roberts, JA; Truloff, N; Ungerer, JP | 1 |
| Clancy, JP; Ehsan, Z | 1 |
| Brown, ED; Farha, MA; Gilmour, C; Lau, CH; Mullen, E; Poole, K | 1 |
| Anagnostopoulos, CD; Apeithi, E; Georgakopoulos, A; Kloudas, S; Pefanis, A; Pianou, NK; Zagklavira, P | 1 |
| Amábile-Cuevas, CF | 1 |
| de Jonge, BL; Karlowsky, JA; Kazmierczak, KM; Nichols, WW; Sahm, DF | 1 |
| Nicolau, DP; Sutherland, CA; Verastegui, JE | 1 |
| Cullina, J; Hauser, AR; Jain, M; McColley, SA; Potter, E; Powers, C; Prickett, MH | 1 |
| Boix, V; Coy, J; Garcinuño, P; Gimeno, L; Merino, E; Portilla, J; Rodríguez, JC; Sánchez-Bautista, A; Sánchez-Paya, J; Santibañez, M | 1 |
| Choudhary, S; Makwana, M; Soni, JP; Tripathi, N | 1 |
| Ansari, S; Chaudhary, N; Dhital, R; Gautam, R; Khatiwada, S; Puri, R; Shrestha, S; Thapa, S | 1 |
| Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
| Hasegawa, H; Izumikawa, K; Kaku, N; Kosai, K; Miyazaki, T; Morinaga, Y; Mukae, H; Takeda, K; Uno, N; Yanagihara, K | 1 |
| Alonso-Isa, M; Benítez-Sala, R; García-Rojo, E; Gil-Moradillo, J; González-Padilla, DA; Justo-Quintas, J; Lara-Isla, A; Medina-Polo, J; Passas-Martínez, JB; Sopeña-Sutil, R; Tejido-Sánchez, Á | 1 |
| Abdi-Ali, A; Gamazo, C; Irache, JM; Sabaeifard, P; Soudi, MR | 1 |
| Han, K; Kang, MW; Kim, JY; Kwon, HJ; Park, YJ; Woo, GJ | 1 |
| Chaudhary, M; Sehgal, R; Shrivastava, SM; Varughese, L | 1 |
| Bayraktar, MR; Işeri, L | 1 |
| Araoka, H; Baba, M; Matsuno, N; Takagi, S; Taniguchi, S; Tatsushima, K; Wake, A; Yoneyama, A | 1 |
| Luemsamran, P; Mekanandha, P; Pornpanich, K; Vangveeravong, S | 1 |
| Adukauskiene, D; Dambrauskiene, A; Jeroch, J; Vitkauskiene, A | 1 |
| Hsieh, FC; Lee, CM; Leung, CH; Liu, CP; Wang, NY; Weng, LC | 1 |
| Adebiyi, OE; Alli, AO; Daini, OA; Ogbolu, DO; Ogunledun, A; Terry, AO | 1 |
| Ambrose, PG; Bhavnani, SM; Dupont, LJ; Forrest, A; Gupta, R; Hammel, J; Mackinson, C; Minic, P; Mulder, GJ; Okusanya, OO | 1 |
| Kalenić, S; Milas, J; Milas, V; Miskulin, M; Puntarić, D; Rudan, S; Vuković, D | 1 |
| Ali-Dinar, T; Colin, AA | 1 |
| Haggard, WO; Noel, SP; Stinner, DJ; Watson, JT; Wenke, JC | 1 |
| Arakawa, Y; Etoh, M; Haruta, T; Hayashi, M; Miki, K; Takegawa, H; Yamane, K | 1 |
| Brescini, L; Cirioni, O; Gabrielli, E; Ghiselli, R; Giacometti, A; Guerrieri, M; Minardi, D; Muzzonigro, G; Orlando, F; Rimini, M; Silvestri, C | 1 |
| Aymard, G; Gutierrez, C; Liu, Z; Lu, Q; Rouby, JJ; Yang, J | 1 |
| Como, J; Escota, G; Kessler, H | 1 |
| Doi, M; Kobayashi, K; Koda, S; Kumon, H; Kusano, N; Kuwabara, M; Shimizu, E; Shimizu, W; Sugai, M | 1 |
| Chong, Y; Hong, HL; Jeong, SH; Kang, JO; Kim, JS; Kim, MN; Lee, K; Park, YJ; Shin, JH; Yong, D | 1 |
| Bozkurt-Güzel, C; Gerçeker, AA | 1 |
| Hsu, LY; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Syahidah, N; Tan, TT; Tan, TY; Teo, J | 1 |
| Araoka, H; Baba, M; Ishii, Y; Mitsuda, T; Mori, S; Moriya, K; Nakamori, Y; Oguri, T; Ohmagari, N; Oishi, T; Okuzumi, K; Tateda, K; Yamaguchi, K; Yoneyama, A | 1 |
| Bedenic, B; Bosnjak, Z; Colinon-Dupuich, C; Cournoyer, B; Orhanovic, S; Plecko, V; Rossolini, GM; Sardelic, S | 1 |
| Chaffanel-Peláez, M; Del Boz, J; Serrano-Martín, MM; Vera-Casaño, A | 1 |
| Almela, M; Cobos-Trigueros, N; Hernández, C; Marco, F; Martínez, JA; Mensa, J; Morata, L; Núñez, R; Soriano, A; Sterzik, H | 1 |
| De Diego, B; García-Berrocal, JR; González-Ramírez, AI; Morales-Avellaneda, T; Mucientes-Rasilla, J; Rodríguez-Alfonso, B | 1 |
| Jahnke, N; Remmington, T; Ryan, G | 1 |
| Amudhan, MS; Balaraman, S; Kamalanathan, A; Sekar, U | 1 |
| Gonda, E; Kilár, F; Kocsis, B; Kustos, I; Kustos, T; Szabó, G | 1 |
| Dudzevicius, V; Sakalauskas, R; Vitkauskiene, A | 1 |
| Adriensen, B; Husson, MO; Loiez, C; Massoni-Cristante, S | 1 |
| Adamidou, M; Bacopoulou, F; Markantonis, SL; Pavlou, E | 1 |
| Malik, A; Shahid, M | 1 |
| Delaere, B; Deltombe, T; Hanson, P; Nisolle, J | 1 |
| Halacová, M; Kotaska, K; Průsa, R; Vávrová, V | 1 |
| Perederko, LV; Polikarpova, SV; Postnikov, SS; Semykin, SIu | 1 |
| Islam, S; Jalal, S; Wretlind, B | 1 |
| Adamis, T; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Mouktaroudi, M; Perrea, D | 1 |
| Friedland, I; Gallagher, G; King, T; Woods, GL | 1 |
| Bertran, S; Gómez, E; Jiménez de Anta, MT; Julià, A; Ruiz, J; Sauca, G; Vila, J; Vila, X | 1 |
| Abe, M; Araki, M; Horimi, T; Nasu, Y; Ono, N; Takahashi, I | 1 |
| Devi, NA; Doss, VA; Parvathi, S; Raju, BA | 1 |
| Ho, SW; Hsueh, PR; Teng, LJ; Tseng, SP | 1 |
| Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A | 1 |
| Pang, XY; Tian, BW; Yang, YJ | 1 |
| Felici, A; Guerrini, M; Marchetti, F; Piccoli, L | 1 |
| Adamis, T; Antonopoulou, A; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Panagou, C; Raftogiannis, M; Tsaganos, T; Tziortzioti, V | 1 |
| Chan, E; Duan, W; Srikumar, S; Zhou, S | 1 |
| Cicek, A; Durmaz, R; Kuzucu, C; Otlu, B; Yetkin, G | 1 |
| Bossuyt, X; Godding, V; Leal, T; Lebecque, P; Reychler, G; Zylberberg, K | 1 |
| Bonetto, M; Carli, M; Cavaliere, M; Cesaro, S; Gavin, P; Magagna, L; Rossi, L; Spiller, M | 1 |
| Alexandrou, I; Chrisofos, M; Geladopoulos, T; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karagianni, V; Koussoulas, V; Koutoukas, P; Kranidioti, H; Pelekanou, E; Sabracos, L; Tsaganos, T; Tzepi, I; Vassiliadis, J | 1 |
| Atmani, S; Bouharrou, A; Hida, M; Larqam, L | 1 |
| Bhat, S; Capitano, B; Fujitani, S; Linden, PK; Paterson, DL; Potoski, BA; Shutt, K | 1 |
| Farooqi, BJ; Hashmi, I; Rafi, S; Sabir, N | 1 |
| Losanoff, JE; Millis, JM | 1 |
| Benslama, A; Charra, B; Hachimi, A; Motaouakkil, S | 1 |
| Fukuoka, N; Houchi, H; Inoue, T; Ishida, T; Kaji, M; Kawazoe, H; Ninomiya, M; Ohnishi, H; Takiguchi, Y; Tanaka, H; Tsuji, S; Yamaguchi, K | 1 |
| Demircioğlu, F; Oren, H | 1 |
| Falkiner, FR; Jacoby, GA; Keane, CT; McCann, SR | 1 |
| Gilly, R; Grenier, B | 1 |
| Bricaire, F; Bure, A; Humbert, G; Vachon, F; Vilde, JL | 1 |
| Catarinelli, L; Celi, F; Crapa, G; De Rosa, F; Frongillo, RF; Luzzi, L; Moretti, MV; Palumbo, M; Rossi, A; Sciannameo, F | 1 |
| Angehrn, P | 1 |
| Fasching, CE; Gerding, DN; Moody, JA; Peterson, LR | 2 |
| Boulton Jones, JM; Gribben, J; Leung, AC; Sleigh, JD | 1 |
| Barnes, RC; Champlin, RE; Gale, RP; Ho, WG; Winston, DJ; Young, LS | 1 |
| Beal, C; Brown, MP; Curry, SH; Embertson, RM; Gronwall, RR; Mayhew, IG | 1 |
| Klastersky, J; Lagast, H; Meunier, F; Piccart, M; Van Laethem, Y; Weerts, D | 1 |
| Aronoff, SC; Klinger, JD | 1 |
| Betts, RF; Chapman, SW; Chonmaitree, T; Messner, M; Mowrer, G; Pincus, P; Robertson, R; Valenti, WM | 1 |
| Jimenez, EM; Lindquist, LB; Montgomerie, JZ; Morrow, JW; Sapico, FL | 1 |
| Davis, SD; Hyndiuk, RA; Sarff, LD | 3 |
| Schmülling, RM; Ullmann, U | 1 |
| Hansen, KD; Meyer, RF | 1 |
| Duncan, IB; Duncan, NH; Rennie, RP | 1 |
| Sanders, CC; Sanders, WE | 1 |
| Barry, AL; Jones, RN; Thornsberry, C | 1 |
| Cagle, GD; Schlech, BA | 1 |
| Immelman, A; van Dyk, E; van Heerden, JS | 1 |
| Baran, D; Klastersky, J; Levy, J | 1 |
| Bayer, AS; Choi, C; Fujita, NK; Guze, LB; Lam, K; Yoshikawa, TT | 1 |
| Bis, W; Jeljaszewicz, J; Kazanowski, A; Kuzniewski, P; Molska, J; Włodarczak, K | 1 |
| Canafax, DM; Peterson, PK; Simmons, RL; Tofte, RW | 1 |
| Cortelezzi, A; Radaelli, F; Savarè, M | 1 |
| Matthews, SJ; Szymczak, EG | 1 |
| Eve, MD; Settle, JA; Smith, JH | 1 |
| Roy, I; Thadepalli, H | 1 |
| Cappelletty, DM; Kang, SL; Palmer, SM; Rybak, MJ | 1 |
| Kitade, M; Moritaka, T; Nakanishi, N; Ueda, N | 1 |
| Ategbo, S; Canis, F; Courcol, R; Husson, MO; Leclerc, H; Turck, D; Vic, P | 1 |
| Baron, D; Bugnon, D; Caillon, J; Drugeon, H; Le Conte, P; Le Floch, R; Le Gallou, F; Potel, G; Xiong, YQ; Zhou, XY | 1 |
| Gaudry, C; Kourilsky, O | 1 |
| Atanasova, I; Markova, B; Staneva, M; Terziivanov, D | 1 |
| Stern, GA | 1 |
| Lamp, KC; McGrath, BJ; Rybak, MJ | 1 |
| Hosokawa, H; Mifune, K; Nakamura, K; Nakano, S; Nyu, S | 1 |
| Donta, I; Giamarellou, H; Karayiannakos, P; Pefanis, A | 1 |
| Alonso, MA; del Palacio, A; Pérez, E; Roiz, MP | 1 |
| Antos, M; Grzybowski, J; Stepińska, M; Trafny, EA | 1 |
| Sturm, W | 1 |
| Leal del Rosal, P | 1 |
| Covi, M; Velluti, G | 1 |
| Esparza-Ahumada, S; Morfin-Otero, R; Rodriguez-Noriega, E | 1 |
| Irby, NL; Sweeney, CR | 1 |
| Das De, S; Thiagarajan, P | 1 |
| Arrouet-Lagandre, C; Ategbo, S; Deschildre, A; Druon, D; Elian, JC; Farriaux, JP; Husson, MO; Loeuille, GA; Tassin, E; Turck, D; Vic, P | 1 |
| Hampel, B; Kraemer, R; Ruedeberg, A; Schaad, UB; Wedgwood, J | 1 |
| Baroni, A; Catalanotti, P; Contaldi, G; Imperatore, F; Luongo, C; Mangoni, G; Marmo, M; Rossi, F; Stefano, S; Tufano, MA | 1 |
| Baron, D; Bayer, AS; Caillon, J; Drugeon, H; Kergueris, MF; Potel, G; Xiong, YQ | 1 |
| Alfaro, DV; Barton, CP; Beverly, DT; Brucker, AJ; Hudson, SJ; Kasowski, EJ; King, LP; Lopez, JD | 1 |
| Ategbo, S; Druon, D; Elian, JC; Farriaux, JP; Gottrand, F; Launay, V; Loeuille, GA; Turck, D; Vic, P | 1 |
| D'Amico, DT; Ng, EW | 1 |
| Blackshear, P; Branch, S; Chernoff, N; Hall, L | 1 |
| Baroni, A; Catalanotti, P; Filippelli, A; Imperatore, F; Luongo, C; Mangoni, G; Marmo, M; Matera, MG; Rossi, F | 1 |
| Diot, P | 1 |
| Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
| Kamiya, A; Mizuno, H; Oie, S; Sawa, A | 1 |
| Aebischer, CC; Bettinelli, A; Bianchetti, MG; Truttmann, AC; von Vigier, RO; Wermuth, B; Zindler-Schmocker, K | 1 |
| Mayer, I; Nagy, E | 1 |
| Burgess, DS; Hastings, RW | 1 |
| Abassi, O; Alharar, R; Bouderka, MA; Guartite, A; Hbid, K; Louardi, H | 1 |
| Aliff, CL; Standridge, JB | 1 |
| Ferranti, S; Menichetti, F; Messina, F; Tascini, C | 1 |
| Andre, C; Arpin, C; Dubois, V; Frigo, C; Melon, B; Melon, M; Quentin, C | 1 |
| Kim, CY; Koh, HJ; Kwon, OW | 1 |
| Delatour, F; Faurisson, F; Jelazko, P | 1 |
| Burgos, A; Campillos, P; Gonzalo, N; López-Lozano, JM; Monnet, DL; Yagüe, A | 1 |
| Halter, J; Lewis, RP; Meyer, RD; White, M | 1 |
| Amirak, ID; Noone, P; Williams, RJ; Wills, MR | 1 |
| Izawa, T; Katakura, K | 1 |
| De Kock, MA; Theron, FP | 1 |
| Schimpff, SC | 1 |
| Fortner, CL; Hahn, DM; Schimpff, SC; Standiford, HC; Wiernik, PH; Young, VM | 1 |
| Aboul-Enein, M; Sherif, M; Soliman, O | 1 |
| Hopefl, AW | 1 |
| Bodey, GP; Feld, R; Rodriguez, V; Valdivieso, M | 2 |
| Dooley, RR; Lau, WK; Osher, AB; Young, LS | 1 |
| Keys, TF; Washington, JA | 1 |
| Washington, JA; Yu, PK | 1 |
| Alford, RH; Leonard, JM; McGee, ZA | 1 |
| Berger, SA; Pollock, AA; Rahal, JJ; Richmond, AS; Simberkoff, MS | 1 |
| Hofstetter, A; Staehler, G | 1 |
| Cox, CE | 1 |
| Hensgens, C; Klastersky, J; Meunier-Carpentier, F | 1 |
| Agre, K; Berman, E; Gooding, PG; Lane, AZ | 1 |
| Hasegawa, Y; Kobayashi, Y; Morishita, T; Tamatani, S; Tomioka, H | 1 |
| Cherubin, CE; Evans, HE; Hochstein, L; Khan, AJ | 1 |
| Grunert, K; Koeppe, P; Langmaack, H; Lode, H | 1 |
| Berger, J; Cates, CY; Fox, LM; Gurwith, MJ; Lank, BA; Mathias, RG; McCullough, DW; Ronald, AR; Stiver, HG | 1 |
| Marget, W; Reindke, B; Versmold, H | 1 |
| Dzierzanowska, D | 1 |
| Mazzei, T; Nicoletti, I; Paradiso, M; Periti, P | 1 |
| Dámaso, D; García-Iglesias, MC; Martínez-Beltrán, J; Moreno-López, M | 1 |
| Agudelo, N; De Vidal, EL; Londono, R; Manotas, R; Ramirez, JI; Trujillo, H; Uribe, A | 1 |
| Bartlett, JG; Gorbach, SL; Louie, TJ; O'Keefe, P; Tally, FP | 1 |
| Agudelo, NH; de Vidal, EL; Ramirez, JI; Trujillo, H; Uribe, A | 1 |
| Homer, PI; Kasbeer, RT; May, DR; Peyman, GA | 1 |
| Kluyskens, P; Pauwels, R; Pijck, J; Soep, H; Van Der Straeten, M; Van Nimmen, L | 1 |
| Lüthy, R | 1 |
| Bartlett, JG; Gorbach, SL; Louie, TJ; Tally, FP; Weinstein, WM | 1 |
| Akoglu, T; Bayik, M; Firatli, T; Gürbüz, O; Korten, V | 1 |
| Anisimova, LA; Boronin, AM; Erova, TE; Moreva, TV | 1 |
| Bailey, EM; Lamp, KC; McGrath, BJ; Rybak, MJ | 1 |
| Auvergnat, JC; Dabernat, H; Froidefond, S; Lemozy, J; Marchou, B; Saivin, S | 1 |
| Hirose, T; Kumamoto, Y; Tanaka, N; Yokoo, A | 2 |
| Zhang, YP | 2 |
| Craig, WA; Ebert, SC; Redington, J | 1 |
| Espinal, D; Garces, G; Mejia de Rodriguez, GI; Mejia, J; Restrepo, C; Restrepo, F; Robledo, C; Robledo, J; Tamayo de Guitierrez, MC; Trujillo, H | 1 |
| Calubiran, OV; Cunha, BA; Schoch, PE | 1 |
| Bayer, AS; Borrelli, RL; Crowell, D; Nast, CC; Norman, DC | 1 |
| Rong, XZ | 1 |
| Bakhache, P; Chivet, C; Douchain, F; Houdas, S; Lebas, L; Pautard, JC | 1 |
| Hu, FR | 1 |
| Maloney, J; Rimland, D; Stephens, DS; Terry, P; Whitney, AM | 1 |
| Gadebusch, HH; Gilfillan, EC; Pelak, BA; Valiant, ME | 1 |
| Buehlmann, U; Guenin, K; Kraemer, R; Schaad, UB; Wedgwood-Krucko, J | 1 |
| Albanese, J; Brunel, MF; Durbec, O; Granthil, C; Soula, F | 1 |
| Bodunkova, LE; Ivanitskaia, LP; Kudinova, MK; Samoĭlova, LN; Viadro, MM | 1 |
| Benson, CE; Orsini, JA; Spencer, PA; Van Miller, E | 1 |
| Gonzales, C; Westblom, TU | 1 |
| Killingsworth, DW; Stern, GA | 1 |
| Bayer, AS; Kim, KS | 1 |
| Arakawa, H; Ishizuka, M; Naito, K; Okura, A; Takeuchi, T; Umezawa, H; Watanabe, Y | 1 |
| Bayer, AS; Bradley, DW; Crowell, DJ; Norman, DC; Yih, J | 1 |
| Auckenthaler, R; Marchou, B; Michéa-Hamzehpour, M; Pechère, JC | 1 |
| Uxová, M; Vrbová, E; Výmola, F | 1 |
| Azadian, BS; Bendig, JW; Samson, DM | 1 |
| Falagas, M; Giamarellou, H; Kanellakopoulou, K; Koratzanis, G; Lelekis, M; Pagona, A; Petrikkos, G; Symeonides, J; Touliatou, K; Tsagarakis, J | 1 |
| Bayer, AS; Kim, KS; Norman, DC | 1 |
| Bailey, EJ; Chandrasekar, PH; Crane, LR | 1 |
| Nightingale, CH; Quintiliani, R; Shyu, WC | 1 |
| Bayer, AS; Hirano, L; Yih, J | 1 |
| Kraemer, R; Schaad, UB; Suter, S; Wedgwood-Krucko, J | 1 |
| Claveau, S; Joly, JR; Lapointe, R; Poirier, A | 1 |
| Chadwick, EG; Shulman, ST; Yogev, R | 2 |
| Colomo-Muñúzuri, AC; Moreno-Martínez, JA; Sánchez-Sánchez, C; Santos-Preciado, JI | 1 |
| Johnson, DE; Thompson, B | 1 |
| Blaser, J; Dudley, M; Zinner, SH | 1 |
| Canawati, HN; Gilmore, DS; Graham, IE; Ibraham, MZ; Montgomerie, JZ; Morrow, JW | 1 |
| Andreoni, M; Concia, E; Fiori, G; Marone, P; Maserati, R; Minoli, L; Suter, F | 1 |
| Borges, LF; Chapman, PH | 1 |
| Grassi, C | 1 |
| Calia, FM; Johnson, DE; Thompson, B | 1 |
| Bayer, AS; Kim, KS; Norman, D | 1 |
| Hanna, BA; Leibowitz, RE; Levine, JF; Maslow, MJ; Pollock, AA; Rahal, JJ; Schaefler, S; Simberkoff, MS | 1 |
| Garau, J; Javaloyas, M; Sanchez, C; Valverde, J | 1 |
| Bayer, AS; Kim, KS; Lam, K; Morrison, JO; Norman, D | 1 |
| Maslow, MJ; Rahal, JJ; Simberkoff, MS | 1 |
| Benuck, I; Traisman, HS | 1 |
| Barton, LL; Fong, CT; Lustig, RH; Walentik, CA | 1 |
| Mordenti, JJ; Nightingale, CH; Quintiliani, R | 1 |
| Junge, RE; MacCoy, DM | 1 |
15 review(s) available for amikacin and Pseudomonas Infections
| Article | Year |
|---|---|
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Cystic Fibrosis; Disease Progression; Forced Expiratory Volume; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Ticarcillin; Tobramycin | 2018 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Topics: Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Child; Cystic Fibrosis; Disease Progression; Gentamicins; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2013 |
Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.
Topics: Administration, Inhalation; Amikacin; Animals; Cystic Fibrosis; Humans; Liposomes; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2014 |
Aerosolized antibiotics in cystic fibrosis: an update.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; Equipment Design; Humans; Levofloxacin; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2014 |
Inhaled liposomal amikacin.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Treatment Outcome | 2014 |
Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
Topics: Administration, Inhalation; Aerosols; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Drug Carriers; Humans; Liposomes; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Cystic Fibrosis; Disease Progression; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Ticarcillin; Tobramycin | 2012 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.
Topics: Amikacin; Animals; Dexamethasone; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Male; Postoperative Complications; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Tissue Plasminogen Activator; Vancomycin | 1993 |
Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Resistance, Microbial; Gentamicins; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections | 2001 |
Empiric therapy of febrile granulocytopenic patients.
Topics: Agranulocytosis; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Blood Transfusion; Cephalosporins; Drug Therapy, Combination; Gentamicins; Granulocytes; Humans; Klebsiella Infections; Neoplasms; Penicillins; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 1979 |
[Aminoglycoside antibiotics from clinical viewpoint].
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Drug Combinations; Enterobacteriaceae Infections; Escherichia coli Infections; Gentamicins; Glomerular Filtration Rate; Kanamycin; Klebsiella Infections; Proteus Infections; Providencia; Pseudomonas Infections; Serratia; Sisomicin; Streptomycin; Tobramycin | 1975 |
Pseudomonas paucimobilis bacteraemia associated with haemodialysis.
Topics: Aged; Aged, 80 and over; Amikacin; Humans; Male; Pseudomonas Infections; Renal Dialysis; Vancomycin | 1990 |
Shunt infections: prevention and treatment.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cerebrospinal Fluid Shunts; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; Gentamicins; Humans; Injections, Intravenous; Injections, Intraventricular; Klebsiella Infections; Leukocytes; Meningitis; Premedication; Pseudomonas Infections; Reoperation; Rifampin; Staphylococcal Infections; Staphylococcus epidermidis; Tobramycin; Vancomycin | 1985 |
Respiratory infections: clinical evaluation.
Topics: Amikacin; Carbenicillin; Cefotaxime; Cystic Fibrosis; Drug Therapy, Combination; Enterobacteriaceae; Haemophilus influenzae; Humans; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Streptococcus; Streptococcus pneumoniae; Tobramycin | 1985 |
28 trial(s) available for amikacin and Pseudomonas Infections
| Article | Year |
|---|---|
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Administration, Inhalation; Adult; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Female; Hospitalization; Humans; Liposomes; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Surveys and Questionnaires; Symptom Assessment; Symptom Flare Up; Tobramycin; Treatment Outcome | 2020 |
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Liposomes; Male; Middle Aged; Pseudomonas Infections; Suspensions | 2021 |
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
Topics: Adolescent; Adult; Amikacin; Analysis of Variance; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Liposomes; Male; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Sputum; Young Adult | 2013 |
Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Pseudomonas Infections; Treatment Outcome | 2008 |
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection.
Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Liposomes; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Young Adult | 2009 |
Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Lung; Male; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tomography, X-Ray Computed | 2011 |
A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Topics: Acinetobacter Infections; Adult; Amikacin; Anti-Bacterial Agents; Area Under Curve; Creatinine; Cross Infection; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Intravenous; Intensive Care Units; Male; Metabolic Clearance Rate; Prospective Studies; Pseudomonas Infections; Superinfection | 2003 |
[Efficacy and safety of cefoperazone/sulbactam in the treatment of children with mucoviscidosis during exacerbation of the bronchopulmonary process].
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Cefoperazone; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Sulbactam; Treatment Outcome | 2003 |
Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Anti-Bacterial Agents; Cefoperazone; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Pseudomonas Infections; Sepsis; Staphylococcal Infections | 1984 |
Short-course aminoglycoside therapy in patients with spinal cord injury. Standard dose versus low dose.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Humans; Injections, Intramuscular; Kanamycin; Proteus Infections; Providencia; Pseudomonas Infections; Random Allocation; Recurrence; Spinal Cord Injuries; Tobramycin; Urinary Bladder, Neurogenic; Urinary Tract Infections | 1980 |
Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Kanamycin; Kinetics; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1982 |
Isepamicin versus amikacin in the treatment of urinary tract infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Escherichia coli Infections; Female; Follow-Up Studies; Gentamicins; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 1995 |
The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cholecystitis; Drug Administration Schedule; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Metronidazole; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections | 1995 |
Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bronchitis; Drug Administration Schedule; Drug Therapy, Combination; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 1995 |
Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Drug Administration Schedule; Escherichia coli Infections; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Proteus Infections; Proteus mirabilis; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus | 1995 |
Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Audiometry; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infant; Kidney Function Tests; Male; Pneumonia, Bacterial; Pseudomonas Infections | 1996 |
Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
Topics: Adolescent; Adult; Amikacin; Anti-Infective Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Pseudomonas Infections; Treatment Outcome | 1997 |
Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis.
Topics: Adolescent; Adult; Amikacin; Anthropometry; Body Composition; Ceftazidime; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Nutritional Status; Opportunistic Infections; Prospective Studies; Pseudomonas Infections; Tobramycin | 1997 |
A simple tool for monitoring nebulized amikacin treatments based on a single urine assay.
Topics: Administration, Inhalation; Adult; Amikacin; Creatinine; Cystic Fibrosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Bacterial; Pseudomonas Infections; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2001 |
Therapy of infection in patients with granulocytopenia.
Topics: Agranulocytosis; Amikacin; Anti-Bacterial Agents; Blood Transfusion; Carbenicillin; Cephalothin; Clinical Trials as Topic; Drug Therapy, Combination; Gentamicins; Granulocytes; Humans; Infections; Kidney; Leukocyte Count; Mycoses; Neoplasms; Pseudomonas Infections; Ticarcillin; Tobramycin | 1977 |
Comparison of amikacin and tobramycin in the treatment of infection in patients with cancer.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Infections; Female; Humans; Kanamycin; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Neoplasms; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tobramycin; Urinary Tract Infections | 1977 |
[Amikacin in urinary tract infections with so-called problem pathogens].
Topics: Amikacin; Clinical Trials as Topic; Drug Evaluation; Escherichia coli Infections; Humans; Kanamycin; Proteus Infections; Pseudomonas Infections; Urinary Tract Infections | 1976 |
Amikacin Therapy of Urinary tract infections.
Topics: Adolescent; Adult; Aged; Amikacin; Clinical Trials as Topic; Enterobacteriaceae Infections; Female; Gentamicins; Humans; Kanamycin; Male; Middle Aged; Pseudomonas Infections; Urinary Tract Infections | 1976 |
Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial.
Topics: Amikacin; Bacterial Infections; Blood Bactericidal Activity; Carbenicillin; Clinical Trials as Topic; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Kanamycin; Penicillin G; Pseudomonas Infections; Sepsis | 1976 |
A review of results of clinical trials with amikacin.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Bone Diseases; Child; Child, Preschool; Clinical Trials as Topic; Drug Resistance, Microbial; Enterobacteriaceae Infections; Humans; Infant; Infant, Newborn; Kanamycin; Middle Aged; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Skin Diseases, Infectious; Urinary Tract Infections | 1976 |
Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
Topics: Aged; Amikacin; Clinical Trials as Topic; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Gentamicins; Humans; Kanamycin; Male; Middle Aged; Pseudomonas; Pseudomonas Infections | 1975 |
Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.
Topics: Adolescent; Adult; Amikacin; Aztreonam; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Pseudomonas Infections; Randomized Controlled Trials as Topic | 1989 |
Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Airway Resistance; Amikacin; Ceftazidime; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Humans; Oxygen Consumption; Pseudomonas Infections; Respiratory Tract Infections; Vital Capacity | 1987 |
265 other study(ies) available for amikacin and Pseudomonas Infections
| Article | Year |
|---|---|
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Risk; Risk Factors | 2007 |
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
Topics: Amino Acid Sequence; Aminoglycosides; beta-Lactamases; Brazil; Carbapenems; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Cefepime; Cephalosporins; Culture Media; Drug Resistance, Multiple; Fluoroquinolones; France; Hospitals, University; Humans; Incidence; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; DNA Primers; DNA-Binding Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Female; Genes, Bacterial; Humans; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Molecular Sequence Data; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Transcription Factors; Virulence | 2008 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Mexico; Models, Genetic; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cloning, Molecular; DNA Primers; DNA, Bacterial; Genes, Bacterial; Genetic Variation; Humans; Imipenem; Integrons; Kinetics; Meropenem; Molecular Sequence Data; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sequence Homology, Amino Acid; Spain; Thienamycins | 2008 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2009 |
Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Brazil; Ceftriaxone; Clindamycin; Drug Resistance, Multiple, Bacterial; Fatal Outcome; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 2009 |
Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
Topics: Alleles; beta-Lactamases; Conjugation, Genetic; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Norway; Pseudomonas aeruginosa; Pseudomonas Infections; Serotyping; Sweden | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Humans; Membrane Transport Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2010 |
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Drug Resistance, Bacterial; Germany; Hospitals, University; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; France; Humans; Microbial Sensitivity Tests; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Potent inhibitors of LpxC for the treatment of Gram-negative infections.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Biphenyl Compounds; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Bacterial; Hydrogen Bonding; Hydroxamic Acids; Mice; Models, Molecular; Molecular Conformation; Phenyl Ethers; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfides; Sulfones | 2012 |
Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Drug Design; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Tetracyclines; Thigh | 2015 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Halogenation; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrrolidinones; Tetracycline Resistance; Tetracyclines | 2017 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Successful treatment of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy.
Topics: Amikacin; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Therapy | 2022 |
Antibiogram and molecular characterization of multi-drug resistant microorganisms isolated from urinary tract infections.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Gentamicins; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Nitrofurantoin; Oxacillin; Pakistan; Pipemidic Acid; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2021 |
Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Ethiopia; Female; Hospitals, Special; Humans; Infant; Infant, Newborn; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Patient Admission; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Treatment Outcome; Young Adult | 2021 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema: A case report.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Drug Combinations; Empyema, Pleural; Female; Humans; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Development of a combination antibiogram for empirical treatments of Pseudomonas aeruginosa at a university-affiliated teaching hospital.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Ceftazidime; Fluoroquinolones; Gentamicins; Hospitals, Teaching; Humans; Levofloxacin; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Universities | 2023 |
High Rates of Extensively Drug-Resistant Pseudomonas aeruginosa in Children with Cystic Fibrosis.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; Reinfection | 2022 |
Emergence of NDM-1-producing
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Clone Cells; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Ribosomal, 16S | 2023 |
The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Disease Models, Animal; Erythromycin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Respiratory Tract Infections | 2023 |
In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Meropenem; Microbial Sensitivity Tests; Models, Theoretical; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Swine | 2023 |
Comparing the Efficacy and Safety of Nebulized Gentamicin Plus Amikacin
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Cross-Sectional Studies; Cystic Fibrosis; Gentamicins; Humans; Pseudomonas Infections; Tobramycin | 2024 |
The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.
Topics: Acute Disease; Amikacin; Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Microbial Sensitivity Tests; Pancreatitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2023 |
Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.
Topics: Alginates; Amikacin; Anti-Bacterial Agents; Arginine; Biofilms; Ciprofloxacin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Nitrates; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Pseudomonas Aeruginosa as the Main Causative Agent of Osteomyelitis and its Susceptibility to Antibiotics.
Topics: Amikacin; Anti-Bacterial Agents; Chronic Disease; Doripenem; Gentamicins; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Endoscopes, Gastrointestinal; Equipment Contamination; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain | 2020 |
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Ceftazidime; Debridement; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Memantine Promotes Bactericidal Effect of Neutrophils Against Infection with
Topics: Acetylcysteine; Amikacin; Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Memantine; Neutrophils; Phosphoproteins; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2022 |
The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Immunocompromised Host; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Ventilators, Mechanical | 2017 |
Evaluation of Carbapenem Resistance Mechanisms and Its Association with Pseudomonas aeruginosa Infections in the Northwest of Iran.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Clone Cells; Female; Gene Expression Regulation, Bacterial; Hospitalization; Humans; Iran; Isoenzymes; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Urinary Tract Infections | 2018 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefoperazone; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Luminescent Measurements; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2018 |
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2018 |
The effect of exposure to sub-inhibitory concentrations of hypochlorite and quaternary ammonium compounds on antimicrobial susceptibility of Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Infective Agents; Ceftazidime; Colistin; Disinfectants; Drug Resistance, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quaternary Ammonium Compounds; Sodium Hypochlorite | 2018 |
In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Drug Resistance, Bacterial; Drug Synergism; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections | 2018 |
Successful treatment of ventriculitis caused by
Topics: Adult; Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Cerebral Ventriculitis; Drug Combinations; Drug Therapy, Combination; Humans; Injections, Intravenous; Injections, Spinal; Klebsiella Infections; Klebsiella pneumoniae; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Ventriculoperitoneal Shunt; Ventriculostomy | 2018 |
Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2019 |
Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
Topics: Administration, Inhalation; Administration, Intravenous; Amikacin; Animals; Anti-Bacterial Agents; Bacterial Load; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fosfomycin; Lung; Meropenem; Nebulizers and Vaporizers; Pneumonia; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Swine; Trachea | 2019 |
Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Chalcones; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Virulence Factors | 2019 |
Nebulized Antibiotics for Multidrug-Resistant Ventilator-Associated Pseudomonas aeruginosa Pneumonia.
Topics: Amikacin; Anti-Bacterial Agents; Fosfomycin; Humans; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
Nationwide surveillance of antimicrobial consumption and resistance to Pseudomonas aeruginosa isolates at 203 Japanese hospitals in 2010.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Utilization; Drug Utilization Review; Hospitals; Humans; Imipenem; Incidence; Japan; Meropenem; Microbial Sensitivity Tests; National Health Programs; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Surveys and Questionnaires; Thienamycins | 2013 |
Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2014 |
Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Area Under Curve; Child; Clinical Trials, Phase II as Topic; Cystic Fibrosis; Female; Humans; Liposomes; Lung; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Young Adult | 2014 |
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.
Topics: Acinetobacter Infections; Adolescent; Age Factors; Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Immunocompromised Host; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Liver Diseases; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Time Factors | 2014 |
Intravesical instillation of amikacin for treatment of a lower urinary tract infection caused by Pseudomonas aeruginosa in a dog.
Topics: Administration, Intravesical; Amikacin; Animals; Anti-Bacterial Agents; Dog Diseases; Dogs; Drug Resistance, Multiple, Bacterial; Female; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 2014 |
A canine case of otitis media examined and cured using a video otoscope.
Topics: Adenoma; Amikacin; Animals; Anti-Bacterial Agents; Dog Diseases; Dogs; Ear Neoplasms; Laser Therapy; Male; Otitis Media; Pseudomonas aeruginosa; Pseudomonas Infections; Video Recording | 2015 |
The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; beta-Lactamases; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Thienamycins | 2015 |
Joint Intratracheal Surfactant-Antibacterial Therapy in Experimental Pseudomonas-Induced Pneumonia.
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Carriers; Drug Combinations; Lung; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Surfactants; Rats, Wistar | 2015 |
In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Female; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Thienamycins | 2015 |
Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gene Expression Regulation, Bacterial; Gentamicins; Heat-Shock Proteins; Humans; Membrane Proteins; Microbial Sensitivity Tests; Paromomycin; Pseudomonas aeruginosa; Pseudomonas Infections; Ribostamycin; Rifampin; Stress, Physiological | 2016 |
A case of paravalvular abscess due to Pseudomonas aeruginosa assessed by 18Fluoro-2-deoxyglucose positron emission tomography/computed tomography.
Topics: Abscess; Aged, 80 and over; Amikacin; Ceftazidime; Fluorodeoxyglucose F18; Heart Valve Diseases; Humans; Male; Multimodal Imaging; Pleural Effusion; Positron Emission Tomography Computed Tomography; Pseudomonas aeruginosa; Pseudomonas Infections; Radiopharmaceuticals; Treatment Outcome | 2016 |
Selection of Amikacin Hyper-Resistant Pseudomonas aeruginosa After Stepwise Exposure to High Amikacin Concentrations.
Topics: Aerosols; Amikacin; Anti-Bacterial Agents; Arginine; Biofilms; Biological Transport; Drug Resistance, Bacterial; Gene Expression; Genes, MDR; Humans; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic | 2017 |
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
Topics: Africa; Amikacin; Anti-Bacterial Agents; Asia; Azabicyclo Compounds; beta-Lactams; Ceftazidime; Colistin; Drug Combinations; Humans; Latin America; Meropenem; Microbial Sensitivity Tests; Middle East; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2016 |
Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Antiporters; Bacterial Proteins; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Gene Expression; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Messenger; Time Factors; Young Adult | 2017 |
Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spain; Thienamycins | 2016 |
Pneumocephalus in Child Following Bilateral Otomastoiditis and Nasal Septum Infection.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Infant; Male; Mastoiditis; Nasal Septum; Otitis Media; Penicillanic Acid; Piperacillin; Pneumocephalus; Pseudomonas Infections; Subdural Effusion; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Growing Menace of Antibacterial Resistance in Clinical Isolates of Pseudomonas aeruginosa in Nepal: An Insight of Beta-Lactamase Production.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Cross-Sectional Studies; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Nepal; Phenotype; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Dibekacin; Disease Models, Animal; Drug Compounding; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Prospective study analyzing risk factors and characteristics of healthcare-associated infections in a Urology ward.
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catheters, Indwelling; Cross Infection; Cystectomy; Drug Resistance, Microbial; Enterococcus; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospital Units; Humans; Immunosuppression Therapy; Incidence; Klebsiella; Klebsiella Infections; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Surgical Wound Infection; Urinary Catheters; Urinary Tract Infections; Urology; Vancomycin | 2017 |
Improved effect of amikacin-loaded poly(D,L-lactide-co-glycolide) nanoparticles against planktonic and biofilm cells of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Biofilms; Cell Survival; Drug Resistance, Multiple, Bacterial; Lactic Acid; Macrophages; Mice; Microbial Sensitivity Tests; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pseudomonas aeruginosa; Pseudomonas Infections; RAW 264.7 Cells | 2017 |
Occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa: a Korean nationwide study.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; DNA, Bacterial; Genes, Bacterial; Humans; Korea; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Changes in the rates of antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa between 2002 and 2004 in a tertiary-care teaching hospital in Turkey.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Bacterial; Hospitals, Teaching; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Turkey | 2008 |
[Case of sepsis caused by multidrug-resistant neutropenic-phase Pseudomonas aeruginosa treated successfully with antibiotic combination therapy].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Treatment Outcome | 2008 |
Orbital cellulitis and endophthalmitis in pseudomonas septicemia.
Topics: Administration, Topical; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Community-Acquired Infections; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Infusions, Intravenous; Injections; Orbital Cellulitis; Pseudomonas aeruginosa; Pseudomonas Infections; Vitreous Body | 2008 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Thienamycins; Wound Infection | 2009 |
Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Infective Agents; Bacteremia; Ceftazidime; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Female; Hospitals, Teaching; Humans; Infection Control; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sulbactam; Taiwan | 2008 |
Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Hospitals, University; Humans; Microbial Sensitivity Tests; Nigeria; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Effect of aminglycoside administration on the occurrence and multiplication of resistant bacteria.
Topics: Amikacin; Aminoglycosides; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up.
Topics: Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Cystic Fibrosis; Drug Therapy, Combination; Female; Forced Expiratory Volume; Gram-Negative Bacterial Infections; Humans; Mycobacterium; Mycobacterium Infections; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia | 2010 |
Local antibiotic delivery using tailorable chitosan sponges: the future of infection control?
Topics: Amikacin; Animals; Anti-Bacterial Agents; Bacterial Infections; Biocompatible Materials; Chitosan; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fractures, Open; Goats; Infection Control; Pseudomonas Infections; Staphylococcal Infections; Vancomycin | 2010 |
[First outbreak report of VIM-1 metallo-beta-lactamase producing Pseudomonas aeruginosa in Japan].
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Aminoglycosides; Bacteriological Techniques; beta-Lactam Resistance; beta-Lactamases; Disease Outbreaks; Female; Fluoroquinolones; Humans; Japan; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Biofilms; Clarithromycin; Coated Materials, Biocompatible; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Stents; Ureteral Diseases | 2011 |
The green cerebrospinal fluid.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; Cerebral Ventriculitis; Cerebrospinal Fluid; Cerebrospinal Fluid Shunts; Color; Diagnosis, Differential; Female; Humans; Hydrocephalus; Injections, Intraventricular; Middle Aged; Oligopeptides; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Subarachnoid Hemorrhage | 2011 |
[Epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated in the Chugoku region of Japan. Infection Forum in the Chugoku Region].
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Imipenem; Japan; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Urine | 2011 |
Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea | 2011 |
Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Phylogeny; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Thienamycins; Time Factors | 2011 |
In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Dibekacin; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Japan; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Statistics, Nonparametric | 2012 |
Infrequent finding of metallo-β-lactamase VIM-2 in carbapenem-resistant Pseudomonas aeruginosa strains from Croatia.
Topics: Amikacin; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Colistin; Croatia; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Serotyping | 2012 |
Facial ecthyma gangrenosum in 2 preterm neonates.
Topics: Amikacin; Facial Dermatoses; Fatal Outcome; Female; Gangrene; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Meropenem; Necrosis; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Skin Diseases, Bacterial; Skin Ulcer; Thienamycins | 2012 |
Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Topics: Adult; Aged; Amikacin; Analysis of Variance; Anti-Bacterial Agents; Bacteremia; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Medication Errors; Middle Aged; Odds Ratio; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Survival Analysis | 2012 |
Clinical-scintigraphy discordance in a case of malignant external otitis.
Topics: Amikacin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Ceftazidime; Cytarabine; Dexamethasone; Female; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multimodal Imaging; Opportunistic Infections; Organoplatinum Compounds; Osteomyelitis; Otitis Externa; Oxaliplatin; Positron-Emission Tomography; Pseudomonas Infections; Skull Base; Temporal Bone; Tomography, X-Ray Computed | 2012 |
bla(IMP) and bla(VIM) mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Imipenem; India; Intensive Care Units; Meropenem; Phenotype; Polymerase Chain Reaction; Pseudomonas; Pseudomonas Infections; Thienamycins | 2012 |
Capillary electrophoresis study of outer membrane proteins of Pseudomonas strains upon antibiotic treatment.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Cefotaxime; Electrophoresis, Capillary; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bronchoalveolar Lavage Fluid; Ceftazidime; Cefuroxime; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fusidic Acid; Gentamicins; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Methicillin; Microbial Sensitivity Tests; Middle Aged; Penicillins; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Staphylococcus aureus; Sulbactam; Vancomycin Resistance | 2003 |
[Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
Topics: Amikacin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
Multidrug-resistant Pseudomonas aeruginosa strains harbouring R-plasmids and AmpC beta-lactamases isolated from hospitalised burn patients in a tertiary care hospital of North India.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Burns; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; India; Inpatients; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors; Transformation, Bacterial | 2003 |
Pyrexia due to pyogenic sacroiliitis with iliopsoas abscess after spinal cord injury.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Fever; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Psoas Abscess; Sacroiliac Joint; Spinal Cord Injuries; Tomography, X-Ray Computed | 2004 |
[Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Child; Computer Simulation; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Male; Models, Biological; Pseudomonas Infections; Respiratory Tract Infections | 2004 |
Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sequence Analysis, DNA | 2004 |
n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
Topics: alpha-Linolenic Acid; Amikacin; Animals; Anti-Bacterial Agents; Arachidonic Acid; Ceftazidime; Cephalosporins; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fatty Acids, Unsaturated; Lipopolysaccharides; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sepsis; Tumor Necrosis Factor-alpha | 2004 |
Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2004 |
Isolation of an amikacin-resistant Escherichia coli strain after tobramycin treatment of previous recurrent episodes of respiratory tract infections caused by Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Respiratory Tract Infections; Tobramycin | 2005 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2004 |
Evaluation on the use of beta-lactamase and aminoglycoside modifying enzyme gene sequences as markers for the early detection of antibiotic resistance profile of Pseudomonas aeruginosa.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Biomarkers; Biotin; Blotting, Southern; Cross Infection; DNA; DNA Primers; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Electrophoresis, Agar Gel; Gentamicins; Humans; Microbial Sensitivity Tests; Nucleic Acid Hybridization; Penicillins; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Sequence Analysis, DNA; Streptomycin; Tobramycin | 2004 |
Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Hospitals, University; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan | 2005 |
[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
Topics: Amikacin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2005 |
In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Ceftazidime; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity | 2005 |
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Immunologic Factors; Kidney; Lipopolysaccharides; Liver; Lung; Male; Malondialdehyde; Monocytes; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Spleen; Tumor Necrosis Factor-alpha | 2006 |
Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Area Under Curve; Drug Synergism; Half-Life; Male; Microbial Sensitivity Tests; Penicillins; Piperacillin; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Survival Analysis | 2006 |
Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Topics: Amikacin; Anti-Bacterial Agents; Critical Illness; Cross Infection; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Turkey | 2006 |
Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2006 |
A simplified method of antibiotic lock therapy for Broviac-Hickman catheters using a CLC 2000 connector device.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacteremia; Catheterization, Central Venous; Catheters, Indwelling; Child; Child, Preschool; Corynebacterium Infections; Female; Humans; Infant; Male; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus epidermidis; Teicoplanin; Vancomycin | 2007 |
Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Cells, Cultured; Humans; Immunologic Factors; Iridoid Glucosides; Iridoids; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrans; Rabbits; Sepsis; Survival | 2006 |
Gangrenous ecthyma in infancy.
Topics: Amikacin; Anti-Bacterial Agents; Gangrene; Humans; Infant; Male; Necrosis; Penicillins; Pseudomonas Infections; Skin Diseases, Bacterial | 2007 |
Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Topics: Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Intensive Care Units; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors | 2007 |
Lumbar osteomyelitis with Pseudomonas.
Topics: Acetic Acid; Amikacin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Lumbosacral Region; Middle Aged; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Giant necrotizing abscess of a liver transplant after gunshot injury.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Humans; Liver Abscess; Liver Transplantation; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Treatment Outcome; Wounds, Gunshot | 2007 |
[Intrathecal use of amikacin and colistin].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Amikacin; Brain Ischemia; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fatal Outcome; Humans; Hydrocephalus; Injections, Spinal; Male; Meningitis, Bacterial; Pseudomonas Infections; Shock, Septic; Surgical Wound Infection; Ventriculostomy | 2008 |
[Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient undergoing allogeneic hematopoietic stem cell transplantation].
Topics: Aged; Amikacin; Aztreonam; Ciprofloxacin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infusions, Intravenous; Male; Pseudomonas Infections; Transplantation, Homologous; Treatment Outcome | 2008 |
Ecthyma gangrenosum: sign of Pseudomonas aeruginosa bacteremia.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Child; Ecthyma; Female; Humans; Imipenem; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Amikacin, gentamicin and tobramycin resistant Pseudomonas aeruginosa in a leukaemic ward. Epidemiology and genetic studies.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Drug Resistance, Microbial; Female; Gentamicins; Humans; Leukemia; Male; Middle Aged; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Urinary Tract Infections | 1982 |
[Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis].
Topics: Adolescent; Amikacin; Azlocillin; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum | 1984 |
[Pseudomonas aeruginosa meningitis treated with azlocillin. 5 cases].
Topics: Adolescent; Adult; Aged; Amikacin; Azlocillin; Drug Therapy, Combination; Female; Humans; Male; Meningitis; Middle Aged; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1984 |
[Our experience with sodium cefoperazone].
Topics: Amikacin; Cefoperazone; Drug Synergism; Escherichia coli Infections; Humans; Meningitis; Pseudomonas Infections; Urinary Tract Infections | 1984 |
In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Cefotaxime; Ceftriaxone; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Gentamicins; Kanamycin; Leukopenia; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1983 |
Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.
Topics: Agranulocytosis; Amikacin; Animals; Anti-Bacterial Agents; Azlocillin; Cefotaxime; Cefoxitin; Ceftizoxime; Disease Models, Animal; Drug Combinations; Female; Hydrogen-Ion Concentration; Kanamycin; Microbial Sensitivity Tests; Neutropenia; Penicillins; Protein Binding; Pseudomonas Infections; Rabbits | 1984 |
Successful treatment of multiresistant pseudomonas peritonitis with combination of azlocillin and amikacin.
Topics: Amikacin; Azlocillin; Female; Humans; Kanamycin; Middle Aged; Penicillin Resistance; Penicillins; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections | 1983 |
Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Bacteria, Anaerobic; Bacterial Infections; Child; Drug Evaluation; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Fever; Gram-Positive Bacteria; Humans; Infusions, Parenteral; Kanamycin; Male; Microbial Sensitivity Tests; Middle Aged; Moxalactam; Piperacillin; Pseudomonas Infections; Random Allocation; Staphylococcal Infections | 1984 |
Amikacin sulfate in mares: pharmacokinetics and body fluid and endometrial concentrations after repeated intramuscular administration.
Topics: Amikacin; Animals; Ascitic Fluid; Body Fluids; Endometrium; Female; Horse Diseases; Horses; Injections, Intramuscular; Kanamycin; Meningitis; Pseudomonas Infections; Synovial Fluid | 1984 |
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Kanamycin; Penicillin Resistance; Piperacillin; Pseudomonas Infections; Ticarcillin | 1984 |
Five-year surveillance of aminoglycoside usage in a university hospital.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Drug Resistance, Microbial; Drug Utilization; Enterobacteriaceae Infections; Gentamicins; Hospitals, University; Humans; Middle Aged; New York; Prospective Studies; Pseudomonas Infections | 1984 |
Relative efficacy of the topical use of amikacin, gentamicin and tobramycin in experimental Pseudomonas keratitis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Disease Models, Animal; Gentamicins; Guinea Pigs; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1980 |
Distribution of Pseudomonas aeruginosa serotypes in bacteriologic specimens and their aminoglycoside resistance.
Topics: Amikacin; Aminoglycosides; Drug Resistance, Microbial; Female; Gentamicins; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Serotyping; Sisomicin; Tobramycin | 1980 |
Amikacin treatment of Pseudomonas-caused corneal ulcer.
Topics: Adolescent; Adult; Amikacin; Burns; Child; Corneal Ulcer; Drug Resistance, Microbial; Eye Injuries; Humans; Kanamycin; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 1980 |
A long-term study of gentamicin-resistant Pseudomonas aeruginosa in a general hospital.
Topics: Amikacin; Cross Infection; Drug Resistance, Microbial; Gentamicins; Hospitals, General; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1981 |
Sisomicin: an aminoglycoside antibiotic that is highly effective against Pseudomonas.
Topics: Amikacin; Animals; Carbenicillin; Gentamicins; Humans; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sisomicin; Ticarcillin; Tobramycin | 1981 |
Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories.
Topics: Amikacin; Drug Resistance, Microbial; Gentamicins; Humans; Kanamycin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
BB-K 122: in vitro and in vivo activity against ocular pathogens.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Bacterial Infections; Eye Diseases; Female; In Vitro Techniques; Kanamycin; Male; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcus aureus; Streptococcus | 1981 |
[The use of amikacin in the treatment of endometritis caused by Pseudomonas aeruginosa in mares].
Topics: Amikacin; Animals; Endometritis; Female; Horse Diseases; Horses; Kanamycin; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 1982 |
Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Endocarditis, Bacterial; Female; Kanamycin; Microbial Sensitivity Tests; Penicillins; Pseudomonas Infections; Rabbits; Ticarcillin | 1983 |
Experimental infection in rabbits evoked by Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae treated with gentamicin, amikacin and sisomicin.
Topics: Amikacin; Animals; Enterobacteriaceae Infections; Escherichia coli Infections; Gentamicins; Kanamycin; Klebsiella Infections; Klebsiella pneumoniae; Proteus Infections; Proteus mirabilis; Pseudomonas Infections; Rabbits; Sisomicin | 1980 |
Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function.
Topics: Adolescent; Adult; Amikacin; Aminoglycosides; Bacterial Infections; Enterobacteriaceae Infections; Female; Humans; Kanamycin; Kidney Transplantation; Labyrinth Diseases; Male; Middle Aged; Pseudomonas Infections | 1982 |
[Pathogenic flora in hematology patients. Gram-negative germs and their in vitro sensitivity to antibiotics].
Topics: Amikacin; Drug Resistance, Microbial; Gentamicins; Hematologic Diseases; Humans; In Vitro Techniques; Pseudomonas; Pseudomonas Infections; Sisomicin; Tobramycin | 1982 |
Case study: Diagnosis and therapy of bacterial osteomyelitis--role of the medical technologist and clinical pharmacist.
Topics: Aged; Amikacin; Carbenicillin; Drug Therapy, Combination; Humans; Kanamycin; Male; Osteomyelitis; Pseudomonas Infections | 1981 |
The use of aminoglycosides in a regional burn unit.
Topics: Adolescent; Adult; Aged; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Burns; Child, Preschool; Humans; Kidney Function Tests; Middle Aged; Pseudomonas Infections | 1981 |
Netilmicin: its in vitro activity and synergism with penicillin compounds.
Topics: Amikacin; Bacteria; Drug Synergism; Enterobacteriaceae Infections; Gentamicins; Humans; Microbial Sensitivity Tests; Netilmicin; Penicillins; Pseudomonas Infections; Sisomicin; Tobramycin | 1980 |
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Drug Therapy, Combination; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Microbial Sensitivity Tests; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 1995 |
[A case of cystic fibrosis in a Japanese student].
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cystic Fibrosis; Drug Therapy, Combination; Erythromycin; Fluoroquinolones; Humans; Japan; Male; Pseudomonas Infections; Quinolones; Respiratory Tract Infections | 1995 |
[Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis].
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Humans; Infusions, Intravenous; Monitoring, Physiologic; Pseudomonas aeruginosa; Pseudomonas Infections | 1995 |
Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both.
Topics: Amikacin; Animals; Aortic Valve; beta-Lactamases; Ceftazidime; Drug Administration Schedule; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Endocarditis; Female; Heart Valve Diseases; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sulbactam | 1995 |
[Is it possible to save an infected catheter?].
Topics: Adult; Amikacin; Anesthesia; Catheterization, Central Venous; Catheters, Indwelling; Drug Resistance, Microbial; Equipment Contamination; Fatal Outcome; Female; Heparin; Humans; Jugular Veins; Pseudomonas; Pseudomonas Infections; Renal Dialysis; Seizures; Sepsis | 1994 |
Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin.
Topics: Algorithms; Amikacin; Animals; Chinchilla; Models, Biological; Pseudomonas Infections; Rabbits | 1994 |
Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
Topics: Amikacin; Colony Count, Microbial; Culture Media; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Imipenem; Microbial Sensitivity Tests; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 1993 |
Circadian variation in amikacin clearance and its effects on efficacy and toxicity in mice with and without immunosuppression.
Topics: Amikacin; Animals; Circadian Rhythm; Cyclophosphamide; Drug Administration Schedule; Female; Immunosuppression Therapy; Male; Mice; Mice, Inbred ICR; Pseudomonas Infections | 1993 |
Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
Topics: Amikacin; Animals; Aortic Valve; Aztreonam; Ceftazidime; Drug Resistance, Microbial; Drug Therapy, Combination; Endocarditis, Bacterial; Microbial Sensitivity Tests; Pseudomonas Infections; Rabbits | 1993 |
[Bacterial keratitis. Report of a case].
Topics: Adult; Amikacin; Contact Lenses, Hydrophilic; Corneal Ulcer; Disease Susceptibility; Gentamicins; Humans; Keratoconjunctivitis; Male; Prednisone; Pseudomonas aeruginosa; Pseudomonas Infections | 1993 |
Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Adhesion; Binding, Competitive; Collagen; Drug Carriers; Humans; Liposomes; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections | 1995 |
Topical treatment of Pseudomonas sp-infected corneal ulcers in horses: 70 cases (1977-1994).
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Corneal Ulcer; Female; Gentamicins; Horse Diseases; Horses; Male; Pseudomonas Infections; Retrospective Studies; Tobramycin | 1996 |
Pyogenic arthritis of the hip following an occult open fracture of the pubic rami--a case report.
Topics: Adult; Amikacin; Arthritis, Infectious; Cefoxitin; Drug Therapy, Combination; Female; Fractures, Open; Hip Joint; Humans; Klebsiella Infections; Pelvic Bones; Pseudomonas Infections | 1996 |
[Effects of hyperbaric oxygenation in skin and pulmonary infections caused by Pseudomonas aeruginosa].
Topics: Amikacin; Animals; Anti-Bacterial Agents; Combined Modality Therapy; Hyperbaric Oxygenation; Lung Diseases; Male; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Skin Diseases, Bacterial | 1996 |
Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Area Under Curve; Drug Resistance, Microbial; Endocarditis, Bacterial; Female; Half-Life; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 1997 |
Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin, and imipenem.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Eye Injuries, Penetrating; Follow-Up Studies; Imipenem; Injections; Pseudomonas aeruginosa; Pseudomonas Infections; Sclera; Swine; Thienamycins; Vitreous Body | 1997 |
Therapeutic efficacy of intravitreal ceftazidime, imipenem, and amikacin in a swine model of posttraumatic Pseudomonas aeruginosa endophthalmitis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Eye Injuries, Penetrating; Imipenem; Pseudomonas Infections; Swine; Vitreous Body | 1997 |
Infectious dermatitis in a ball python (Python regius) colony.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Boidae; Cefotaxime; Cephalosporins; Dermatitis; Disease Outbreaks; Fatal Outcome; Female; Male; Proteus Infections; Proteus vulgaris; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Infectious | 1998 |
Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Combined Modality Therapy; Hyperbaric Oxygenation; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Skin Diseases, Bacterial | 1999 |
[Antibiotics and nebulization].
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections | 1999 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
Aminoglycosides and renal magnesium homeostasis in humans.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Electrolytes; Female; Homeostasis; Humans; Kidney; Lung Diseases; Magnesium; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 2000 |
Evaluation of post-antibiotic effects of antipseudomonal antibiotics using an automated system.
Topics: 4-Quinolones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Automation; Ceftazidime; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Netilmicin; Ofloxacin; Pefloxacin; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections | 2000 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
[Stab wound of the spinal cord complicated by meningitis and subarachnoid fistula].
Topics: Adult; Amikacin; Drug Therapy, Combination; Fistula; Humans; Imipenem; Male; Meningitis, Bacterial; Pleura; Pleural Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Spinal Cord Injuries; Subarachnoid Space; Wounds, Stab | 2001 |
Aerosolized amikacin in the treatment of Pseudomonas pneumonia in the nursing home setting.
Topics: Administration, Inhalation; Aerosols; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Homes for the Aged; Humans; Male; Nursing Homes; Pneumonia, Bacterial; Pseudomonas Infections | 2001 |
In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate.
Topics: Amikacin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Colistin; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Middle Aged; Pseudomonas Infections; Rifampin | 2000 |
Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.
Topics: Adult; Amikacin; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Ribotyping | 2001 |
Translimbal approach for intravitreal injection in endophthalmitis after phacoemulsification.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anesthesia, Local; Dexamethasone; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Injections; Limbus Corneae; Male; Phacoemulsification; Pseudomonas Infections; Vancomycin; Vitreous Body | 2001 |
Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.
Topics: Amikacin; Aminoglycosides; California; Carbenicillin; Cross Infection; Enterobacteriaceae Infections; Gentamicins; Hospitals, General; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Sisomicin; Tobramycin | 1976 |
Amikacin resistance developing in patients with Pseudomonas aeruginosa bronchopneumonia.
Topics: Amikacin; Bronchopneumonia; Drug Resistance, Microbial; Female; Humans; Kanamycin; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 1977 |
Bacteriologic cure of experimental Pseudomonas keratitis.
Topics: Administration, Topical; Amikacin; Animals; Carbenicillin; Drug Evaluation; Guinea Pigs; Keratitis; Male; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1978 |
Therapeutic effect of topical antibiotic on untreated eye in experimental keratitis.
Topics: Absorption; Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Biological Availability; Cornea; Drug Evaluation, Preclinical; Guinea Pigs; Kanamycin; Keratitis; Male; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 1978 |
[Treatment of Pseudomonas aeruginosa pneumonia with amikacin (author's transl)].
Topics: Adult; Amikacin; Female; Gentamicins; Humans; Kanamycin; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 1979 |
Clinical experience with amikacin, a new aminoglycoside antibiotic.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Enterobacteriaceae Infections; Female; Humans; Kanamycin; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases; Male; Middle Aged; Pseudomonas Infections | 1977 |
Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients.
Topics: Adult; Agranulocytosis; Amikacin; Cephalothin; Drug Therapy, Combination; Escherichia coli Infections; Female; Humans; Kanamycin; Male; Neoplasms; Pseudomonas Infections | 1977 |
Amikacin in the treatment of genito-urinary tract infections in cancer patients.
Topics: Adult; Aged; Amikacin; Cystitis; Escherichia coli Infections; Female; Humans; Kanamycin; Male; Middle Aged; Pseudomonas Infections; Pyelonephritis; Urinary Bladder Neoplasms | 1978 |
Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Topics: Acute Disease; Adolescent; Adult; Amikacin; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Kanamycin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 1977 |
Gentamicin-resistant Pseudomonas aeruginosa: Mayo Clinic Experience, 1970-1976.
Topics: Amikacin; Carbenicillin; Drug Therapy, Combination; Gentamicins; Hospitals, General; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1977 |
Antimicrobial susceptibility of gentamicin-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Carbenicillin; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Sisomicin; Tobramycin | 1977 |
Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Cross Infection; Drug Resistance, Microbial; Enterobacteriaceae Infections; Female; Gentamicins; Humans; In Vitro Techniques; Infant; Kanamycin; Male; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Serratia marcescens; Urinary Tract Infections | 1978 |
Amikacin therapy for serious gram-negative infection.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Gentamicins; Humans; Kanamycin; Kidney; Klebsiella Infections; Middle Aged; Pseudomonas Infections; Sepsis | 1977 |
[Amikacin treatment of septicemia due to gentamicin-resistant gram-negative bacilli (author's transl)].
Topics: Aged; Amikacin; Aorta, Thoracic; Aortic Aneurysm; Cephaloridine; Drug Resistance, Microbial; Gentamicins; Humans; Kanamycin; Male; Microbial Sensitivity Tests; Parkinson Disease; Proteus Infections; Proteus mirabilis; Pseudomonas aeruginosa; Pseudomonas Infections; Subarachnoid Hemorrhage | 1975 |
In-vitro comparison of four antipseudomonal antibiotics in a general hospital.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbenicillin; Child; Child, Preschool; Dose-Response Relationship, Drug; Gentamicins; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Middle Aged; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1976 |
Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Bronchitis; Chronic Disease; Enterobacteriaceae Infections; Female; Humans; Kanamycin; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 1976 |
Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
Topics: Adolescent; Adult; Aged; Amikacin; Aminoglycosides; Bacterial Infections; Enterobacteriaceae Infections; Humans; Kanamycin; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Urinary Tract Infections | 1976 |
Use of Amikacin in a hospital for children: microbiological and clinical studies.
Topics: Amikacin; Aminoglycosides; Bacterial Infections; Child; Child, Preschool; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Kanamycin; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Urinary Tract Infections | 1976 |
[New aminoglycoside antibiotics].
Topics: Amikacin; Anti-Bacterial Agents; Bacteria; Drug Resistance, Microbial; Enterobacteriaceae Infections; Humans; Kanamycin; Pseudomonas Infections; Tobramycin | 1977 |
Amikacin in obstetric, gynecologic, and neonatal infections: laboratory and clinical studies.
Topics: Amikacin; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fetal Blood; Gentamicins; Humans; Infant, Newborn; Infant, Newborn, Diseases; Kanamycin; Kidney Failure, Chronic; Pregnancy; Pregnancy Complications, Infectious; Pseudomonas Infections; Urinary Tract Infections | 1976 |
Preliminary clinical trial with amikacin in chronic recurrent gram-negative bacterial infections refractory to other antimicrobial agents.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Chronic Disease; Enterobacteriaceae Infections; Female; Humans; Kanamycin; Male; Middle Aged; Peritonitis; Pseudomonas Infections; Recurrence; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 1976 |
Clinical and laboratory studies with amikacin in newborns, infants, and children.
Topics: Adolescent; Amikacin; Bacterial Infections; Child; Child, Preschool; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Kanamycin; Male; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections | 1976 |
Amikacin for treatment of infections in patients with malignant diseases.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Blood Cell Count; Enterobacteriaceae Infections; Female; Humans; Kanamycin; Male; Middle Aged; Neoplasms; Neutrophils; Pseudomonas Infections | 1976 |
Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
Topics: Amikacin; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Kanamycin; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections; Sepsis | 1976 |
Amikacin (BBK8) in infections due to gram-negative organisms in children over the age of one month.
Topics: Adolescent; Amikacin; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Enterobacteriaceae Infections; Female; Humans; Infant; Injections, Intramuscular; Kanamycin; Male; Microbial Sensitivity Tests; Pseudomonas Infections | 1976 |
Penetration of amikacin into the aphakic eye.
Topics: Absorption; Amikacin; Animals; Aqueous Humor; Cataract Extraction; Endophthalmitis; Kanamycin; Lens, Crystalline; Ophthalmic Solutions; Postoperative Complications; Pseudomonas Infections; Rats; Vitreous Body | 1975 |
Amikacin in the treatment of gram-negative bronchopulmonary infections.
Topics: Acute Disease; Adult; Aged; Amikacin; Enterobacteriaceae Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Kanamycin; Middle Aged; Pseudomonas Infections; Respiratory Tract Infections | 1976 |
Subcutaneous nodules caused by Pseudomonas aeruginosa: healing without incision and drainage.
Topics: Amikacin; Ceftazidime; Fluconazole; Humans; Male; Middle Aged; Multiple Myeloma; Myositis; Pseudomonas Infections; Skin Diseases, Bacterial | 1992 |
[Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas].
Topics: Amikacin; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors | 1992 |
Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
Topics: Amikacin; Aztreonam; Cefepime; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Half-Life; Humans; In Vitro Techniques; Pseudomonas Infections | 1992 |
[Resistance to antibiotic treatment produced in a model of experimental Pseudomonas aeruginosa peritonitis].
Topics: Amikacin; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Drug Therapy, Combination; Imipenem; Mice; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections | 1992 |
[Study of the effect of combination therapy of human granulocyte-colony stimulating factor (G-CSF) and amikacin on experimental pyelonephritis induced by Pseudomonas aeruginosa in neutropenic mice].
Topics: Amikacin; Animals; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Mice; Mice, Inbred Strains; Neutropenia; Pseudomonas Infections; Pyelonephritis | 1990 |
[Study of the increasing effect of therapeutic efficacy of amikacin in combination with human granulocyte-colony stimulating factor (G-CSF) against experimental urinary tract infection in diabetic mice].
Topics: Amikacin; Animals; Anti-Infective Agents, Urinary; Diabetes Mellitus, Experimental; Drug Evaluation; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Mice; Mice, Inbred Strains; Pseudomonas Infections; Urinary Tract Infections | 1991 |
[Common pathogens in burn infection and changes in their drug sensitivity].
Topics: Amikacin; Burns; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Proteus; Proteus Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 1991 |
Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.
Topics: Amikacin; Animals; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Kidney; Klebsiella pneumoniae; Lung Diseases; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Specific Pathogen-Free Organisms; Thigh | 1991 |
Single daily dose amikacin in paediatric patients with severe gram-negative infections.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Infant; Lactams; Prospective Studies; Pseudomonas Infections | 1991 |
Intravegetation antimicrobial distribution in aortic endocarditis analyzed by computer-generated model. Implications for treatment.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aortic Diseases; Computer Simulation; Diffusion; Drug Administration Schedule; Endocarditis, Bacterial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 1990 |
[Experimental study of pulmonary infection and its systemic dissemination in the early stage of severe burn].
Topics: Amikacin; Animals; Burns; Disease Susceptibility; Endotoxins; Female; Male; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sepsis | 1990 |
Variability of aminoglycosides pharmacokinesis in C.F. patients in relation with certain clinical parameters.
Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Male; Pneumonia; Pseudomonas Infections; Tobramycin | 1990 |
Infectious crystalline keratopathy caused by Mycobacterium fortuitum and Pseudomonas aeruginosa.
Topics: Adult; Amikacin; Carbenicillin; Corneal Diseases; Eye Infections, Bacterial; Female; Humans; Keratoplasty, Penetrating; Mycobacterium Infections; Pseudomonas Infections | 1990 |
Analysis of amikacin-resistant Pseudomonas aeruginosa developing in patients receiving amikacin.
Topics: Amikacin; Bacterial Outer Membrane Proteins; Bacterial Proteins; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Humans; Lipopolysaccharides; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 1989 |
L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Drug Synergism; Female; Gentamicins; Isoindoles; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1989 |
[Opportunistic infection and systemic dissemination in burns].
Topics: Amikacin; Burns; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Opportunistic Infections; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia | 1989 |
[Fulminating Pseudomonas maltophilia septicemia during treatment with imipenem and amikacin].
Topics: Amikacin; Drug Resistance, Microbial; Humans; Imipenem; Male; Middle Aged; Pseudomonas; Pseudomonas Infections; Sepsis | 1989 |
[Combined chemotherapy of experimental infection in neutropenia].
Topics: Agranulocytosis; Amikacin; Animals; Azlocillin; Cefotaxime; Drug Synergism; Drug Therapy, Combination; Escherichia coli Infections; Immune Tolerance; Klebsiella Infections; Mice; Neutropenia; Opportunistic Infections; Pseudomonas Infections | 1989 |
Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
Topics: Amikacin; Animals; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Gentamicins; Horse Diseases; Horses; Klebsiella; Microbial Sensitivity Tests; Proteus; Pseudomonas; Pseudomonas Infections | 1989 |
Massive hemothorax and Groshong catheters.
Topics: Adult; Amikacin; Catheterization, Central Venous; Ceftazidime; Hemothorax; Humans; Male; Pseudomonas Infections; Subclavian Vein; Urinary Tract Infections | 1989 |
Pseudomonas keratitis associated with the use of disposable soft contact lenses. Case report.
Topics: Adolescent; Amikacin; Carbenicillin; Contact Lenses, Extended-Wear; Corneal Diseases; Corneal Ulcer; Disposable Equipment; Drug Therapy, Combination; Edema; Humans; Keratitis; Male; Pseudomonas Infections | 1989 |
In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Azlocillin; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Kanamycin; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Time Factors | 1986 |
Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms.
Topics: Adjuvants, Immunologic; Amikacin; Animals; Female; Glycine; Mice; Mice, Inbred ICR; Muramidase; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Superoxides | 1987 |
Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis.
Topics: Amikacin; Animals; Aortic Valve; Ceftazidime; Endocarditis, Bacterial; Heart Valves; Pseudomonas Infections; Rabbits; Tricuspid Valve | 1988 |
Combination therapy: a way to limit emergence of resistance?
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Female; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Norfloxacin; Pefloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 1986 |
Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae.
Topics: Amikacin; Animals; Ceftazidime; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Serratia marcescens | 1987 |
In vivo effect of aminoglycoside on Pseudomonas aeruginosa in experiment.
Topics: Amikacin; Aminoglycosides; Animals; Mice; Mice, Inbred Strains; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections | 1986 |
Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin.
Topics: Adult; Amikacin; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Leukemia; Pseudomonas aeruginosa; Pseudomonas Infections | 1986 |
Nosocomial consequences of antibiotic usage.
Topics: Amikacin; Bacteriuria; Cross Infection; Drug Resistance, Microbial; Drug Utilization; Gentamicins; Greece; Hospitals, General; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 1986 |
Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.
Topics: Amikacin; Animals; Cell Membrane Permeability; Drug Resistance, Microbial; Endocarditis, Bacterial; Freeze Fracturing; Gentamicins; Kanamycin; Microscopy, Electron; Microscopy, Electron, Scanning; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Virulence | 1987 |
Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients.
Topics: Adult; Aged; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cefsulodin; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1987 |
Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination.
Topics: Agranulocytosis; Amikacin; Animals; Ceftazidime; Drug Therapy, Combination; Female; Kinetics; Microbial Sensitivity Tests; Neutropenia; Penicillins; Peritoneal Cavity; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Strains; Ticarcillin | 1987 |
Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Drug Resistance, Microbial; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Norfloxacin; Pefloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 1988 |
Bacteremia caused by Pseudomonas mesophilica.
Topics: Amikacin; Catheterization, Central Venous; Catheters, Indwelling; Humans; Male; Middle Aged; Pseudomonas Infections; Sepsis | 1988 |
Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis.
Topics: Agranulocytosis; Amikacin; Animals; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae Infections; Imipenem; Kanamycin; Kinetics; Klebsiella Infections; Microbial Sensitivity Tests; Neutropenia; Pseudomonas Infections; Rats; Sepsis; Serratia marcescens; Thienamycins | 1986 |
[Malignant otitis externa. Presentation of a case].
Topics: Amikacin; Cefotaxime; Humans; Infant; Male; Otitis Externa; Pseudomonas Infections | 1987 |
Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.
Topics: Agranulocytosis; Amikacin; Animals; Azlocillin; Drug Therapy, Combination; Female; Kanamycin; Microbial Sensitivity Tests; Neutropenia; Penicillin Resistance; Penicillins; Pseudomonas Infections; Rats; Rats, Inbred Strains; Sepsis; Ticarcillin | 1986 |
In vitro models for the study of combination antibiotic therapy in neutropenic patients.
Topics: Agranulocytosis; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Azlocillin; Bacterial Infections; Carbenicillin; Cefazolin; Cephalothin; Drug Therapy, Combination; Gentamicins; Humans; Models, Biological; Neutropenia; Pseudomonas Infections; Risk | 1986 |
Combination antibiotic therapy in pediatrics.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Deficiency Syndromes; Infant; Infant, Newborn; Kanamycin; Lactams; Neutropenia; Peritoneal Dialysis, Continuous Ambulatory; Pseudomonas Infections; Risk | 1986 |
Cefsulodin in treatment of Pseudomonas urinary tract infection in patients with spinal cord injury. Comparison with aminoglycosides.
Topics: Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cefsulodin; Humans; Male; Middle Aged; Pseudomonas Infections; Spinal Cord Injuries; Time Factors; Tobramycin; Urinary Tract Infections | 1986 |
Ceftazidime in the therapy of pseudomonal meningitis.
Topics: Adolescent; Adult; Amikacin; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Parenteral; Injections, Intraventricular; Injections, Spinal; Male; Meningitis; Middle Aged; Pseudomonas Infections | 1985 |
Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Neutropenia; Penicillin Resistance; Peritonitis; Piperacillin; Pseudomonas Infections; Rats; Rats, Inbred Strains; Sepsis | 1985 |
Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Aortic Valve; Blood Bactericidal Activity; Ceftazidime; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Endocarditis, Bacterial; Female; Heart Valve Diseases; Kanamycin; Microbial Sensitivity Tests; Pseudomonas Infections; Rabbits | 1985 |
Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
Topics: Acetyltransferases; Amikacin; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Bacteria; Humans; Kanamycin; New York; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors | 1985 |
Bilateral and symmetrical osteomyelitis due to gram-negative bacilli. A report on two cases.
Topics: Adult; Amikacin; Ampicillin; Female; Gram-Negative Bacteria; Humans; Middle Aged; Osteomyelitis; Proteus Infections; Proteus mirabilis; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 1985 |
Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
Topics: Amikacin; Animals; Ceftazidime; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Kanamycin; Microbial Sensitivity Tests; Myocardium; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 1985 |
Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
Topics: Aged; Amikacin; Aminoglycosides; Cefotaxime; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Kanamycin; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Serratia marcescens | 1985 |
Malignant external otitis in a diabetic adolescent.
Topics: Adult; Amikacin; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Male; Otitis Externa; Piperacillin; Pseudomonas Infections | 1986 |
Neonatal septicemia due to Pseudomonas aeruginosa.
Topics: Adult; Amikacin; Ampicillin; Female; Humans; Infant, Newborn; Kanamycin; Male; Pregnancy; Pseudomonas Infections; Sepsis; Ticarcillin | 1986 |
Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Bacterial Infections; Drug Combinations; Female; Infusions, Parenteral; Kinetics; Pseudomonas Infections; Rats; Rats, Inbred Strains; Ticarcillin | 1985 |
Amikacin therapy for Pseudomonas cellulitis in an Amazon parrot.
Topics: Amikacin; Animals; Bird Diseases; Cellulitis; Kanamycin; Parrots; Pseudomonas Infections; Psittaciformes | 1985 |